TL;DR
A new study from Israel links finasteride, a widely used hair-loss drug, to increased risks of depression, brain inflammation, and suicidal thoughts. Despite internal warnings dating back over a decade, the US FDA delayed labeling suicide risk until 2022. Researchers now urge regulators to reassess the drug’s safety, particularly for cosmetic use, while exploring safer alternatives like stevioside-enhanced minoxidil patches.
What the new research reveals
A recent Israeli study published in the Journal of Clinical Psychiatry has reignited debate around the safety of finasteride, a drug taken by millions worldwide for male pattern baldness and enlarged prostate.
According to lead author Dr. Mayer Brezis, of the Hadassah, Hebrew University Medical Center, the evidence now goes beyond isolated case reports:
“The evidence is no longer anecdotal. We now see consistent patterns across diverse populations. And the consequences may have been tragic.”
The study found that long-term use of finasteride may cause persistent brain inflammation and structural changes in the hippocampus, the brain region involved in learning, memory, and emotional regulation.
These neurological effects may explain the surge in reported mood disorders, anxiety, and suicidal thoughts among finasteride users.
Finasteride: from breakthrough to controversy
Finasteride, first approved by the U.S. Food and Drug Administration (FDA) in the 1990s, was marketed under brand names like Propecia (for hair loss) and Proscar (for prostate enlargement).
Its popularity soared due to its effectiveness in slowing or reversing male pattern baldness. Yet, since the early 2000s, patient reports began surfacing about persistent side effects even after discontinuing the drug, a condition now informally called Post-Finasteride Syndrome (PFS).
Despite internal discussions and external warnings, the FDA’s acknowledgment of mental health risks came gradually:
- 2002 – Early warnings about depression surface.
- 2011 – FDA adds “depression” as a possible side effect.
- 2022 – “Suicidal ideation” was officially added to the drug’s label.
Internal FDA documents reveal delayed action
Dr. Brezis’ investigation uncovered redacted FDA documents from 2010 suggesting that agency experts had already advised adding suicide risk to the drug’s labeling more than a decade earlier.
“The advice was rejected by the agency without disclosing the internal discussion and the rationale for the final decision,” Brezis wrote.
These internal memos reportedly contained confidential estimates of people potentially affected by finasteride-related side effects. By 2011, the FDA had logged only 18 suicides, but Brezis believes the true global toll may be in the thousands due to underreporting and data gaps.
The findings raise serious questions about regulatory transparency and the influence of pharmaceutical lobbying on drug safety decisions.
The manufacturer under scrutiny
The study also criticizes Merck & Co., the original manufacturer of finasteride, for failing to conduct robust long-term safety studies — particularly concerning neuropsychiatric outcomes.
Brezis argues that both Merck and global regulators neglected early warning signs:
“Regulators should have demanded more comprehensive safety data before allowing finasteride’s mass marketing for cosmetic purposes.”
He recommends suspending the sale of finasteride for hair loss until independent safety reviews are completed.
Searching for safer alternatives
While concerns grow around finasteride’s psychological effects, researchers are exploring safer and more natural treatments for androgenetic alopecia (pattern baldness).
A new study from the University of Sydney introduced a potential breakthrough: a microneedle patch that combines minoxidil (the active ingredient in Rogaine) with stevioside, a natural compound from the stevia plant.
This innovation significantly improves drug absorption and hair follicle stimulation, at least in early mouse trials.
“Using stevioside to enhance minoxidil delivery represents a promising step toward more effective and natural treatments for hair loss,” said co-author Dr. Lifeng Kang.
If proven effective in humans, the stevioside-minoxidil patch could offer a non-hormonal alternative for millions currently dependent on finasteride.
Understanding the wider impact
A global health concern
Androgenetic alopecia affects around 80 million Americans, including 50% of men and 25% of women by age 50. The sheer size of this market underscores the stakes of finasteride’s safety debate.
Mental health under the microscope
The finasteride controversy also reflects a broader issue: the underestimation of mental health risks in non-psychiatric drugs. Many medications, especially those that alter hormones, can have unforeseen neurological effects that manifest years later.
What happens next?
The study has renewed calls for:
- Global re-evaluation of finasteride’s safety for cosmetic use.
- Public access to FDA’s redacted documents.
- Greater awareness among healthcare providers prescribing finasteride to young men.
While millions continue to take the drug safely, experts agree that informed consent is critical. Patients should be briefed about potential long-term psychological effects and monitored regularly for mood changes.
The takeaway
Finasteride’s story illustrates the tension between cosmetic medicine and mental health accountability. Once celebrated as a miracle pill for hair loss, it’s now under scrutiny for potentially life-threatening side effects that were long minimized.
As regulators revisit its safety profile and researchers explore natural alternatives like stevioside-minoxidil patches, one thing is clear, the conversation around beauty, biology, and mental health is only beginning.